Compare COVID-19 Oral Antivirals

February 2022

You'll be asked about the new COVID-19 oral antivirals nirmatrelvir/ritonavir (Paxlovid) and molnupiravir.

Eligibility. Educate that these meds are for outpatients with a positive COVID-19 test who are at high risk of developing severe illness (diabetes, etc)...regardless of vaccination status.

Nirmatrelvir/ritonavir is for age 12 and up...molnupiravir is for 18 and up. Either is started within 5 days of symptoms...and used bid for 5 days. Patients don't currently have to pay for them.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote